Navigation Links
AEterna Zentaris to Announce First Quarter 2009 Financial and Operating Results and Hold Annual Shareholder Meeting on May 6, 2009
Date:4/30/2009

QUEBEC CITY, April 30 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, will announce its first quarter 2009 financial and operating results before market open on Wednesday, May 6, 2009. The Company will host a conference call and webcast to discuss these results later that same day at 3:30 p.m., Eastern Time.

Participants may access the live webcast via the Company's website at www.aezsinc.com in the "Investors" section, or by telephone using the following numbers: 416-644-3422, 514-807-8791 or 800-587-1893. A replay of the webcast will also be available on the Company's website for a period of 30 days.

The Company further announced that it will hold its Annual Shareholder Meeting also on Wednesday, May 6, 2009 starting at 10:30 a.m. Eastern Time, in Rooms 6 and 7 of the Centre Sheraton Montreal Hotel, 1201 Rene-Levesque Boulevard West, in Montreal.

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology with proven expertise in drug discovery, development and commercialization. News releases and additional information are available at www.aezsinc.com.


'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. AEterna Zentaris Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement
2. AEterna Zentaris Presents Phase 1 Results for AEZS-112 in Patients with Advanced Cancer and Lymphoma at AACR Annual Meeting in Denver
3. AEterna Zentaris Presents Two Posters on its PI3K Inhibitor Compound, AEZS-126, at AACR Annual Meeting
4. AEterna Zentaris To Present Data on Anticancer Compounds AEZS-112 and AEZS-126 at AACR Annual Meeting
5. AEterna Zentaris Reports Fourth Quarter and Full-Year 2008 Financial and Operating Results
6. AEterna Zentaris to Announce Fourth Quarter and Full-Year 2008 Financial and Operating Results on March 11, 2009
7. AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia
8. AEterna Zentaris to Present at Upcoming RBC Capital Markets Healthcare Conference
9. AEterna Zentaris Closes Sale of Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
10. AEterna Zentaris Reports Third Quarter 2008 Financial and Operating Results
11. AEterna Zentaris to Announce Third Quarter 2008 Financial and Operating Results on November 13, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... ... registry built on the secure online PatientCrossroads platform, has exceeded both its one-year ... have joined the PROMPT study, which seeks to advance understanding of the hereditary ...
(Date:2/10/2016)... CA (PRWEB) , ... February 10, 2016 , ... Cenna ... agents for the treatment of Alzheimer’s disease, announced today it has been selected to ... 18th at the Breakers in Palm Beach, Florida. The purpose of the Forum ...
(Date:2/9/2016)... , Feb. 9, 2016  Regenicin, Inc. (OTC ... specializing in the development and commercialization of regenerative ... tissues and organs, recently reported the Company,s operating ... quarter of 2016. Lonza America , ... 2015 fiscal year in the process of consummating ...
(Date:2/9/2016)... , ... February 09, 2016 , ... ... latest innovations on its free and validated Electronic Data Capture (EDC) system ClinCaptureand ... Outsourcing in Clinical Trials West Coast 2016 Conference in San Mateo, California on ...
Breaking Biology Technology:
(Date:2/3/2016)... -- --> --> Fourth quarter 2015: ... 1,187% compared with fourth quarter of 2014. Gross margin was ... 30.0). Earnings per share increased to SEK 6.39 (loss: 0.49). ... 74.7). , --> --> ... M (233.6), up 1,142% compared with 2014. Gross margin was ...
(Date:2/3/2016)... 2016 http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ... "Emotion Detection and Recognition Market by ... Software Tools (Facial Expression, Voice Recognition and ... - Global forecast to 2020" report ... http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) has announced the addition of ...
(Date:2/2/2016)... Feb. 2, 2016 Checkpoint Inhibitors for ... Market Are you interested in the future ... for checkpoint inhibitors. Visiongain,s report gives those predictions ... and national level. Avoid falling behind in ... opportunities and revenues those emerging cancer therapies can ...
Breaking Biology News(10 mins):